Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vicarious Surgical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vicarious Surgical's regulatory disclosures and financial reporting.
Vicarious Surgical Inc. filing a Rule 144 notice that lists the proposed sale of 1,902 shares of Class A common stock following a 02/19/2026 restricted stock lapse. The broker shown is UBS Financial Services with a filing date of 02/20/2026.
The filing also reports prior sales of 239 shares on 12/03/2025 by Sammy Khalifa. The notice records standard transaction details for an insider sale under Rule 144.
Vicarious Surgical Inc. filed a Rule 144 notice indicating proposed sales of Class A common stock. The filing lists 2,377 shares tied to a restricted stock lapse on 02/19/2026. It also records a prior sale of 463 shares on 12/03/2025 by Adam Sachs.
Vicarious Surgical Inc. filed an 8-K describing updated severance and change in control protections for its Chief Executive Officer and Chief Financial Officer. CEO Stephen From received an amendment to his employment agreement that provides severance if he is terminated without cause or resigns for good reason, including enhanced cash payments, continued COBRA health premiums and full vesting of time-based equity if the termination occurs in connection with a change in control.
CFO Sarah Romano entered into a new Executive Severance and Change in Control Agreement with similar protections, scaled to her role. Her agreement also offers higher severance multiples, extended COBRA coverage and full vesting of time-based equity awards if a qualifying termination occurs within a defined window around a change in control. Both arrangements require signing a separation agreement with a release and restrictive covenants.
Vicarious Surgical Inc. reported the results of a special stockholder meeting held on January 9, 2026. Stockholders voted on a single proposal related to warrants previously issued by the company.
Holders of Class A and Class B common stock, voting together as a single class, approved the exercise of warrants issued on October 7, 2025 to purchase up to an aggregate of 2,300,000 shares of Class A common stock. The proposal passed with 14,991,093 votes in favor, 23,052 votes against, and 2,894 abstentions.
There were 2,591,229 shares of Class A and Class B common stock present or represented by proxy at the meeting, representing approximately 78.18% of the outstanding total voting power entitled to vote, which was sufficient to constitute a quorum.